Pakistan Science Abstracts
Article details & metrics
No Detail Found!!
The effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity.
Author(s):
1. Muhammad Athar Khwaja: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad, Pakistan
2. Gul Nawaz: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad, Pakistan
3. Shujah Muhammad: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad, Pakistan
4. Muhammad Imran Jamil: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad, Pakistan
5. Muhammad Faisal: Department of Urology and Kidney Pathology, Shifa International Hospital, Islamabad, Pakistan
6. Saeed Akhter: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad, Pakistan
Abstract:
Objective: To determine the effect of two weeks preoperative finasteride therapy in reducing prostate vascularity in terms of mean microvessel density (MVD) and expression of VEGF in prostate urothelium among patients of BPH by comparing with controls. Study Design: Randomized controlled trial. Place and Duration of Study: Shifa International Hospital, Islamabad, from January 2013 to January 2014. Methodology: A total of 80 patients of Benign Prostatic Hyperplasia (BPH) planned for Trans-Urethral Resection of Prostate (TURP) having prostate size of more than 40 grams on trans-abdominal ultrasonography was randomized into two groups, each group having 40 patients. The finasteride group (Group A) was prescribed oral 5 mg of finasteride daily for 2 weeks before surgery. The control group (Group B) did not receive any agent. After 2 weeks, TURP was performed and prostate samples were sent for histopathological determination of MVD and expression of VEGF. Results: The mean age of patients was 66.21 ±10.08 years, ranging from 48 to 86 years. The mean prostate gland size was comparable in both groups (55 ±10.7 vs. 58.1 ±10.8 grams, p=0.21). Mean MVD in finasteride group (20.25 ±10.3) was significantly lower as compared to control group (48.9 ±22.6, p < 0.001). Similarly expression of VEGF was also significantly lower in finasteride group (30%) as compared to control group (65%) [p= 0.0017]. Mean MVD had a significant weak correlation with the size of prostate gland on Pearson correlation test (2-tailed) with r = 0.222. Conclusion: Finasteride reduces microvessel density and hence prostate vascularity with only 2-week therapy and the mean MVD is clearly correlated with size of prostate.
Page(s): 213-215
DOI: DOI not available
Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 3, Year: 2016
Keywords:
Keywords are not available for this article.
References:
[1] BoyleP,NapalkovP., 1995.The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension,Scand J Urol Nephrol Suppl 168 7 -12
[2] SmithAB,CarsonCC, 2009.Fanasteride in the treatment of patients with benign prostatic hyperplasia: a review,Ther Clin Risk Manag 5 535 -45
[3] HochbergDA,BasilloteJB,ArmenakasNA,VasovicL,ShevchukM,PareekG, 2002.Decreased suburothelial prostatic microvessel density in finasteride treated prostate: a possible mechanism for reduced bleeding in benign prostatic hyperplasia,J Urol 167 1731 -3
[4] FoleySJ,SolomanLZ,WedderburnAW, 2000.A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride,J Urol 163 496 -8
[5] OzdalOL,OzdenC,BenliK,GokkayaS,BulutS,MemisA, 2005.Effect of short term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of prostate: a randomized controlled study,Prostate Cancer Prostatic Dis 8 215 -8
[6] ZongHT,PengXX,YangCC,ZhangY., 2011.A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia,Asian J Androl 13 812 -8
[7] MemisA,OzdenC,OzdalOL,GuzelO,HanO,SeckinS, 2008.Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia,Urol Int 80 177 -80
[8] DonohueJF,Hayned,ThomasDR,FosterMC, 2005.Randomized, placebo controlled trial showing that finasteride reduces prostate vascularity rapidly within 2 weeks,BJU Int 96 1319 -22
[9] De BerardinisE,AntoniniG,BusettoGM,GentileV,Di SilverioF,RossiA, 2008.Reduced intraoperative bleeding during transurethral resection of the prostate: evaluation of finasteride, vascular endothelial growth factor, and CD34,Current Prostate Reports 6 123 -7
[10] McVaryKT,RoehrbornCG,AvinsAL, 2011.Update on AUA guideline on the management of benign prostatic hyperplasia,J Urol 185 1793 -1803
[11] McVaryKT,RoehrbornCG,AvinsAL,BarryMJ,BruskewitzRC,DonnellRF, 2010.American Urological Association Guidelines: management of benign prostatic hyperplasia BPH),American Urological Association -
[12] ZaitsuM,TonookaA,MikamiK,HattoriM,TakeshimaY,UekusaT, 2013.A Dual 5α-Reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia,ISRN Urol 863489 -
[13] RassweilerJ,TeberD,KuntzR,HofmanR, 2006.Complication of transurethral resection of prostate - incidence, management and prevention,Eur Urol 50 969 -80
[14] AboumarzoukOM,AslamMZ,WedderburnA,TurnerK,HughesO,KynastonHG, 2013.Should finasteride be routinely given preoperatively for TURP? ISRN Urol, 458353 -
[15] KavanaghLE,JackGS,LawrentschukN, 2011.Prevention and management of TURP-related hemorrhage,Nat Rev Urol 8 504 -14
[16] JiangY,Long YF, 2010.Effects of finasteride on hematuria associated with benign prostatic hyperplasia: a meta-analysis,Zhonghua Nan KeXue 16 726 -9
[17] VasdevN,KumarA,VeeratterapillayR,ThorpeAC, 2013.Hematuria secondary to benign prostatic hyperplasia: retrospective analysis of 166 men identified in a single one stop hematuria clinic,Curr Urol 6 146 -9
[18] NikhilVasdev, 2013.Hematuria secondary to benign prostatic hyperplasia: retrospective analysis of 166 men identified in a single one stop hematuria,Clinic Curr Urol 6 146 -9
[19] PastoreAL,MarianiS,BarreseF,PalleschiG,ValentiniAM,PaciniL, 2013.Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss,J Endourol 27 68 -70
[20] SugieS,MukaiS,TsukinoH,IwamotoH,KobayashiT,TodaY, 2014.Effect of dutasteride on microvessel density in benign prostatic hyperplasia,In Vivo 28 355 -9
[21] HyunJH,ChoKH,HanDS,KimJB,ChangYS, 2009.The effect of finasteride on microvessel density and expression of vascular endothelial growth factor and 5 α-reductase in prostatic hyperplasia,Korean J Urol 50 947 -54
[22] LiuXD,YangYR,LuYP,ZhangXH,LiFY, 2003.Preoperative finasteride on decreasing operative bleeding during transurethral resection of prostate,Chin J Urol 24 694 -6
[23] PareekG,ShevchukM,ArmenakasNA, 2003.The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients,J Urol 169 20 -3
[24] HaggstromS,TørringN,MøllerK,JensenE,Lund L, 2002.Effects of finasteride on vascular endothelial growth factor - a placebo controlled randomized study in BPH patients,Scand J Urol Nephrol 36 182 -7
Citations
Citations are not available for this document.
0

Citations

0

Downloads

11

Views